Close Menu

NEW YORK – Merck yesterday announced positive progression-free survival data for its anti-PD-1 therapy pembrolizumab (Keytruda) combined with chemotherapy as a first-line treatment for patients with metastatic triple-negative breast cancer.

According to results from the Phase III KEYNOTE-355 trial comparing pembrolizumab in combination with chemotherapy against chemotherapy and placebo, patients treated with the pembrolizumab combination experienced a significant improvement in progression-free survival, translating to a reduced risk of disease progression or death.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.